<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04863742</url>
  </required_header>
  <id_info>
    <org_study_id>ENHANCE</org_study_id>
    <nct_id>NCT04863742</nct_id>
  </id_info>
  <brief_title>Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing FLACS With Premium IOL</brief_title>
  <acronym>ENHANCE</acronym>
  <official_title>Evaluation Of Vision Recovery And Comfort Index In Patients With Borderline/Mild Dry Eyes Undergoing Femtosecond Laser-Assisted Cataract Surgery With Premium Intraocular Lens - The ENHANCE Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Medical Doctors PLLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sight Medical Doctors PLLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open-label, single-center, randomized, head-to-head,&#xD;
      investigator-sponsored clinical study. It aims to investigate the vision recovery and patient&#xD;
      comfort in borderline/mild dry eye disease patients undergoing FLACS with Premium PCIOL&#xD;
      (i.e., Panoptix, Toric IOL (spherical/multifocal), ReStor, Symfony), receiving a 0.4mg&#xD;
      dexamethasone intracanalicular insert when compared to patients receiving standard of care&#xD;
      prednisolone acetate 1%.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, open-label, single-center, randomized, head-to-head,&#xD;
      investigator-sponsored clinical study. It aims to investigate the vision recovery and patient&#xD;
      comfort in borderline/mild dry eye disease patients undergoing FLACS with Premium PCIOL&#xD;
      (i.e., Panoptix, Toric IOL (spherical/multifocal), ReStor, Symfony), receiving a 0.4mg&#xD;
      dexamethasone intracanalicular insert when compared to patients receiving standard of care&#xD;
      prednisolone acetate 1%. After screening a given patient for inclusion and exclusion&#xD;
      criteria, and gaining informed consent, a total of 30 patients will be randomized into two&#xD;
      groups:&#xD;
&#xD;
      Group 1: 15 patients will undergo bilateral FLACS + Premium PCIOL in separate days and will&#xD;
      receive a 0.4mg dexamethasone intracanalicular insert at the days of each surgery.&#xD;
&#xD;
      Group 2: 15 patients will undergo bilateral FLACS + Premium PCIOL in separate days and will&#xD;
      receive prednisolone acetate 1% QID/ 1 week, TID/ 1 week, BID/1 week, QD/ 1 week regimen&#xD;
      starting at the days of each surgery.&#xD;
&#xD;
      All patient eyes will receive Prolensa 0.07% ophthalmic solution QD for 4 weeks starting 3&#xD;
      days prior to surgery and Besivance 0.6% eye drops TID/starting 3 days prior to surgery.&#xD;
&#xD;
      Per enrolled eye, the study period will last for approximately 30 days after surgery,&#xD;
      consisting of three postop follow-up visits (six total postop visits per patient). At Day 1,&#xD;
      Day 7 and Day 30, primary and secondary endpoints will be assessed alongside standard-of-care&#xD;
      procedures. SPEED questionnaire will be assessed by a masked survey administrator. Adjusting&#xD;
      for enrollment period, the study will last a total of approximately 12 months, including&#xD;
      submission for publication/ presentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">April 26, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA)</measure>
    <time_frame>Baseline, Post-Operative Day 7 and Day 30</time_frame>
    <description>As measured by Best Corrected Visual Acuity (BCVA) from baseline and at 1 week and 30 days after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change in uncorrected Visual Acuity (VA)</measure>
    <time_frame>Baseline, Post-Operative Day 7 and Day 30</time_frame>
    <description>As measured by uncorrected VA from baseline and at 1 week and 30 days after surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in Standardized Patient Evaluation of Eye Dryness (SPEED) score</measure>
    <time_frame>Baseline, Post-Operative Day 7 and Day 30</time_frame>
    <description>As measured by SPEED score from baseline and at 1 week and 30 days after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction with vision at 1 week and 30 days after surgery</measure>
    <time_frame>Post-Operative Day 7 and Day 30</time_frame>
    <description>As measured by patient satisfaction survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of artificial tear drops dosed per day</measure>
    <time_frame>30 Day tear log.</time_frame>
    <description>As measured by patient daily log.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in tear break-up time (TBUT)</measure>
    <time_frame>Baseline and at POD 7 and POD 30</time_frame>
    <description>As measured by TBUT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in tear osmolarity</measure>
    <time_frame>Baseline and at POD 7 and POD 30</time_frame>
    <description>As measured by tear osmolarity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in corneal staining</measure>
    <time_frame>Baseline and at POD 7 and POD 30</time_frame>
    <description>As measured by corneal staining</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in (Central Subfield Thickness) CST</measure>
    <time_frame>Post-Operative Day 7 and 30</time_frame>
    <description>As measured by CST</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Dextenza Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Prednisolone Acetate 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>sustained released dexamethasone, 0.4mg</description>
    <arm_group_label>Dextenza Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisolone Acetate</intervention_name>
    <description>Prednisolone Acetate 1% QID x 1week, TID x 1week, BID x1 week, QD x1 week.</description>
    <arm_group_label>Prednisolone Acetate 1%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Demonstrate objective signs of Boderline/ Mild Ocular Surface Disease (OSD) [defined&#xD;
             as mild symptoms, mild conjunctival staining (&lt;2+ Superficial Punctate Keratitis),&#xD;
             Tear Break-up Time &lt;12s] or demonstrate symptoms of OSD determined by SPEED&#xD;
             questionnaire (SPEED Score &lt;10).&#xD;
&#xD;
          2. Nucleus sclerosis up to 2+ planning to undergo FLACS + Premium PCIOL in both eyes.&#xD;
&#xD;
          3. Ability to provide informed consent for procedures&#xD;
&#xD;
          4. Ability to attend scheduled follow up visits&#xD;
&#xD;
          5. No other corneal pathology to create unknown variability&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18&#xD;
&#xD;
          2. Pregnancy/currently breast-feeding&#xD;
&#xD;
          3. Inability to provide informed consent&#xD;
&#xD;
          4. Documented adverse reaction to steroid (e.g. &quot;steroid responder&quot;, allergy, etc)&#xD;
&#xD;
          5. Punctal stenosis&#xD;
&#xD;
          6. Previous corneal transplant surgery or refractive surgery&#xD;
&#xD;
          7. Concurrent use of topical steroid eye drops&#xD;
&#xD;
          8. Systemic, topical or intravitreal steroid use within 1 month of baseline&#xD;
&#xD;
          9. Active history of chronic or recurrent inflammatory eye disease in either eye&#xD;
&#xD;
         10. History of ocular herpetic infection (inclusive of Herpes Simplex 1/2, Varicella&#xD;
             Zoster, Epstein Barr, Cytomegalovirus)&#xD;
&#xD;
         11. History of neurotrophic keratitis, uncontrolled diabetes, or other disease entities&#xD;
             that may preclude proper healing&#xD;
&#xD;
         12. Diagnosis of Glaucoma or use of topical glaucoma drops&#xD;
&#xD;
         13. Participation in other studies in the last 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Passarelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sight Medical Doctors PLLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John Passarelli, MD</last_name>
    <phone>6312314455</phone>
    <email>msingleton@sightmd.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marshel Singleton, MSN, FNP</last_name>
    <phone>6312314455</phone>
    <email>msingleton@sightmd.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>SightMD, LIASC</name>
      <address>
        <city>Brentwood</city>
        <state>New York</state>
        <zip>11717</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Passarelli, MD</last_name>
      <phone>631-231-4455</phone>
      <email>msingleton@sightmd.com</email>
    </contact>
    <contact_backup>
      <last_name>Marshel Singleton, MSN, FNP</last_name>
      <phone>6312314455</phone>
      <email>msingleton@sightmd.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sight Medical Doctors PLLC</investigator_affiliation>
    <investigator_full_name>Dr. John Passarelli</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

